China-based Hangzhou DAC Biotech Co., Ltd announced a licensing agreement with Janssen Pharmaceuticals Inc., a unit of US major Johnson & Johnson, to collaborate on the development of antibody drug conjugates (ADCs). The partnership will leverage DAC Bio’s proprietary ADC platform and Janssen’s antibody expertise for up to five targets.
Deal Details
Under the agreement, Janssen will supply proprietary antibodies, while DAC Bio will utilize its ADC platform to develop product candidates. Johnson & Johnson Innovation facilitated the deal, with its investment arm JJDC making an equity investment in DAC Bio. Financial terms include undisclosed upfront payments, cost reimbursements, milestone payments, and royalties on global sales for DAC Bio.
Strategic Implications
DAC Bio will harness its intellectual property and ADC technology, while Janssen will drive clinical development and commercialization. The collaboration aims to accelerate ADC candidate development, combining DAC Bio’s platform with Janssen’s antibody assets to target unmet therapeutic needs.-Fineline Info & Tech
